We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current PVCT market cap is 48.88M. The company's latest EPS is USD -0.0074 and P/E is -16.22.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 989k | 558k |
| Operating Income | -6.3M | -4.96M | -4.67M | -3.43M | -2.9M |
| Net Income | -6.92M | -6.68M | -5.54M | -3.56M | -3.1M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.48M | 589k | 3.51M | 2.04M | 1.45M |
| Total Liabilities | 25.55M | 30.8M | 7.7M | 8.27M | 9.04M |
| Total Equity | -24.07M | -30.21M | -4.19M | -6.23M | -7.59M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.19M | -4.09M | -1.01M | -3.04M | -2.57M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 6.75M | 3.6M | 4.02M | 1.37M | 2.19M |
| Market Cap | 48.88M |
| Price to Earnings Ratio | -16.22 |
| Price to Sales Ratio | 92.31 |
| Price to Cash Ratio | 600 |
| Price to Book Ratio | -6.64 |
| Dividend Yield | - |
| Shares Outstanding | 420.28M |
| Average Volume (1 week) | 245.02k |
| Average Volume (1 Month) | 169.78k |
| 52 Week Change | 16.18% |
| 52 Week High | 0.2245 |
| 52 Week Low | 0.0445 |
| Spread (Intraday) | 0 (1.79%) |
| Company Name | Provectus Biopharmaceuticals Inc (QB) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
